Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Cited In for PubMed (Select 2986930)

1.

Investigation of cross-species translatability of pharmacological MRI in awake nonhuman primate - a buprenorphine challenge study.

Seah S, Asad AB, Baumgartner R, Feng D, Williams DS, Manigbas E, Beaver JD, Reese T, Henry B, Evelhoch JL, Chin CL.

PLoS One. 2014 Oct 22;9(10):e110432. doi: 10.1371/journal.pone.0110432. eCollection 2014.

2.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19.

PMID:
25179217
3.

NOP receptor mediates anti-analgesia induced by agonist-antagonist opioids.

Gear RW, Bogen O, Ferrari LF, Green PG, Levine JD.

Neuroscience. 2014 Jan 17;257:139-48. doi: 10.1016/j.neuroscience.2013.10.061. Epub 2013 Nov 1.

4.

Pharmacological strategies for detoxification.

Diaper AM, Law FD, Melichar JK.

Br J Clin Pharmacol. 2014 Feb;77(2):302-14. doi: 10.1111/bcp.12245. Review.

5.

Mu opioids and their receptors: evolution of a concept.

Pasternak GW, Pan YX.

Pharmacol Rev. 2013 Sep 27;65(4):1257-317. doi: 10.1124/pr.112.007138. Print 2013. Review.

6.

Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC.

J Pharmacol Exp Ther. 2013 Jul;346(1):11-22. doi: 10.1124/jpet.113.203984. Epub 2013 May 7.

7.

Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Eschenroeder AC, Vestal-Laborde AA, Sanchez ES, Robinson SE, Sato-Bigbee C.

Glia. 2012 Jan;60(1):125-36. doi: 10.1002/glia.21253. Epub 2011 Oct 14.

8.

The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review.

Dunn KE, Sigmon SC, Strain EC, Heil SH, Higgins ST.

Drug Alcohol Depend. 2011 Dec 1;119(1-2):1-9. doi: 10.1016/j.drugalcdep.2011.05.033. Epub 2011 Jul 8. Review.

9.

7α-Methoxy-carbonyl-6,7,8,14-tetra-hydro-6,14-endo-ethenothebaine.

Odabaşoğlu M, Yavuz S, Pamir O, Yıldırır Y, Büyükgüngör O.

Acta Crystallogr Sect E Struct Rep Online. 2009 Mar 25;65(Pt 4):o864. doi: 10.1107/S1600536809009362.

11.

Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Duke AN, Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2010 Aug;211(3):303-12. doi: 10.1007/s00213-010-1898-4. Epub 2010 Jun 25.

12.

Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network.

Martino S, Brigham GS, Higgins C, Gallon S, Freese TE, Albright LM, Hulsey EG, Krom L, Storti SA, Perl H, Nugent CD, Pintello D, Condon TP.

J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S31-43. doi: 10.1016/j.jsat.2009.12.013.

13.

Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2009 Dec;331(3):946-53. doi: 10.1124/jpet.109.156711. Epub 2009 Aug 27.

14.

The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Farid WO, Dunlop SA, Tait RJ, Hulse GK.

Curr Neuropharmacol. 2008 Jun;6(2):125-50. doi: 10.2174/157015908784533842.

15.

Buprenorphine: a unique drug with complex pharmacology.

Lutfy K, Cowan A.

Curr Neuropharmacol. 2004 Oct;2(4):395-402. doi: 10.2174/1570159043359477.

16.

Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.

Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P.

JAMA. 2008 Nov 5;300(17):2003-11. doi: 10.1001/jama.2008.574. Erratum in: JAMA. 2009 Feb 25;301(8):830. JAMA. 2013 Apr 10;309(14):1461.

17.

Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.

Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, Rosenblum A.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):222-30. doi: 10.1016/j.drugalcdep.2008.08.006. Epub 2008 Oct 18.

18.

Opioids and the treatment of chronic pain: controversies, current status, and future directions.

Rosenblum A, Marsch LA, Joseph H, Portenoy RK.

Exp Clin Psychopharmacol. 2008 Oct;16(5):405-16. doi: 10.1037/a0013628. Review.

19.
20.

Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M.

Biol Psychiatry. 2007 Jan 1;61(1):4-12. Epub 2006 Mar 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk